Home
Clinical Trials
A Study of E7090 in Participa...

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Last Updated: 2025-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-22

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed gemcitabine-based combination chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

NCT05678270

Intrahepatic Cholangiocarcinoma (ICC)

RECRUITING PHASE2

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

NCT04353375

Advanced Intrahepatic Cholangiocarcinoma Solid Tumor, Adult

RECRUITING PHASE2/PHASE3

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

NCT06777316

Intrahepatic Cholangiocarcinoma (Icc) Cholangiocarcinoma Other Solid Tumors, Adult +9 more

RECRUITING PHASE1/PHASE2

Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT02400788

Hepatocellular Carcinoma

COMPLETED PHASE1/PHASE2

PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

NCT05864105

Hepatocellular Carcinoma

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholangiocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

E7090 140 mg

Participants will receive E7090 140 mg (milligram), tablets orally once daily (QD), in 28-days treatment cycle until disease progression, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination.

Group Type EXPERIMENTAL

E7090

Intervention Type DRUG

E7090 tablets orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

E7090

E7090 tablets orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants with a histologically or cytologically diagnosis of intrahepatic or perihilar cholangiocarcinoma who agree to provide archival tumor sample or residual biopsy sample, or agree with tumor biopsy.
2. Participants who have confirmed FGFR2 gene fusion of tumor by fluorescence in situ hybridization (FISH) in central laboratory. FGFR2 gene fusion confirmed by the same FISH assay in another test/study will be discussed with the sponsor and agreed on a case by case basis.
3. Participants with surgically unresectable or advanced/metastatic disease who have received at least one prior chemotherapy including gemcitabine-based combination chemotherapy (example: gemcitabine and cisplatin)

a. Prior adjuvant chemotherapy is allowed if relapse was within 6 months after last administration.
4. Measurable disease meeting the following criteria:

1. At least 1 lesion of \>=1.0 centimeter (cm) in the longest diameter for a non-lymph node or \>=1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI).
2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.
5. Corrected serum calcium less than or equal to (\<=) upper limit of normal (ULN).
6. Phosphate \<=ULN.
7. Participants with Performance Status (PS) score of 0-1 established by Eastern Cooperative Oncology Group (ECOG).
8. Participants who are expected to survive for 3 months or longer after starting administration of the investigational drug.
9. Washout period required from the end of prior treatment to the start of E7090 administration will be as follows

1. Antibody and other investigational drugs : \>=4 weeks
2. Prior chemotherapy (except small-molecule targeted therapy), surgical therapy, radiation therapy：\>=3 weeks
3. Endocrine therapy, immunotherapy, small-molecule targeted therapy: \>=2 weeks

8. Participants with prior therapy targeting FGFR2.
9. Participants who need the use of drugs or foods that strongly inhibits or induces the metabolizing enzyme cytochrome P450 (CYP) 3A4 during study treatment (there must be a time interval of \>= 7 days since the final use of these drugs or foods by the start of study treatment).

Exclusion Criteria

1. Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (example: radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
2. Concomitant active infection requiring systemic treatment (except hepatitis B or C virus-infected participants who are under anti-viral treatment).
3. Participants who test positive for human immunodeficiency virus (HIV antibody) at Screening 2.
4. Child-Pugh score B or C.
5. Moderate or severe ascites extending from the pelvis to the liver surface.
6. Following ocular disorders

1. Current evidence of Grade 2 or higher corneal disorder
2. Current evidence of active macula disorder (example: age-related macular degeneration, central serous chorioretinal disease)

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

Site Status